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Abstract: This review will explore the latest advancements spanning several facets of 
wound healing, including biologics, skin substitutes, biomembranes and scaffolds. 
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Abbreviations  
RNA Ribonucleic Acid 
IL-6 Interleukin 6 
TNF-α Tumor Necrosis Factor Alpha 
LTC4 Leukotriene C4 
TXB2 Thromboxane B2 
UVB Ultraviolet B 
MIF Migration Inhibitory Factor 
NO Nitric Oxide 
RCT Randomized Controlled Trial 
TBSA Total Body Surface Area 
STSG Split-Thickness Skin Graft 
COX-2 Cyclooxygenase-2 
IL-1β Interleukin-1 beta 
NF-κB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
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IL-10 Interleukin 10 
ATP Adenosine Triphosphate 
KATP Potassium Channels 
CEA Cultured Epithelial Autograft 
HDE Humanitarian Device Exemption 
DFU Diabetic Foot Ulcers 
PMA Premarket Approval 
LOS Length of Stay 
TGF-β Transforming Growth Factor-beta 
CACs Circulating Angiogenic Cells 
OPN Osteopontin 
CCPE Collagen Coated Porous Polyethylene 
PMB Poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) 
UPPE Uncoated Porous Polyethylene 
DNA Deoxyribonucleic Acid 
P3HT Photosensitive Polymer Poly (3-hexylthiophene) 
CGS Collagen/Gelatin Sponge 
1. Introduction 
The healing of wounds is a complex process that involves the activation and synchronization of 
intracellular, intercellular and extracellular elements, including coagulatory and inflammatory events, 
fibrous tissue accretion, deposition of collagen, epithelialization, wound contraction, tissue granulation and 
remodeling [1]. This process occurs via activation of local and systemic cells to restore tissue integrity 
through regeneration and scar formation, and often these cumulative processes result in satisfactory 
repair of damaged sites. Disruptions caused by tissue loss, inadequate blood flow, and comorbid 
disease states can lead to chronic wounds that are difficult to manage [2]. There are many strategies 
that have been applied to the treatment of wounds in the past. Early on, these were based on empirical 
deduction and unsubstantiated determinations. Although there was a general resistance to new concepts 
and modalities that impeded progress, advancements in the treatment of wounds have, nevertheless, 
evolved [3]. Over the past two decades, advancements in the clinical understanding of wounds and their 
pathophysiology have commanded significant biomedical innovations in the treatment of acute, chronic, 
and other types of wounds. This review will explore the latest advancements spanning several facets of 
wound healing, including biologics, skin substitutes, biomembranes and scaffolds. 
2. Biologics for Wound Healing 
2.1. Description 
Biologic wound healing therapies are those that are intended to facilitate the re-establishment of the 
innate repair mechanisms, and may involve the application of active biological agents, such as  
plant-derived active biomolecules which exhibit antioxidant, antimicrobial, or anti-inflammatory attributes. 
Biologic dressings prevent evaporative water loss, heat loss, protein and electrolyte loss, and 
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contamination. They also permit autolytic debridement and develop a granular wound bed. Biological skin 
equivalents, epidermal growth factors, stem cell therapies, and tissue engineering might also be utilized [2].  
2.2. Mechanisms and Indications 
Monoterpenes represent an extensive and varied family of naturally occurring terpene-based 
chemical compounds that comprise the majority of essential oils. These compounds exhibit  
anti-inflammatory, antibacterial, and antioxidant attributes [4,5]. The primary mechanisms proposed 
for various monoterpenes encompass: antimicrobial activity (inhibition of microorganism ribonucleic 
acid (RNA) and protein biosynthesis); anti-inflammation (lowers the generation of interleukin 6 (IL-6) 
and tumor necrosis factor alpha (TNF-α) in mast cells, inhibition and alteration of leukotriene C4 
(LTC4) release and thromboxane B2 (TXB2) release, respectively); antioxidation (inhibits the production 
of ultraviolet B (UVB)-induced free radicals photoprotective effects and oxidative stress); fibroblast 
growth and macrophage migration inhibitory factor (MIF) effects. The anti-inflammatory action of the 
monoterpenes is often correlated to their wound-healing effects. Monoterpenes include compounds 
such as borneol, thymol, α-terpineol, genipin, aucubin, d-Limonene and sericin that have either direct 
or indirect activities in wound healing. Although monoterpenes are poorly studied in the context of 
wound healing, studies suggest that they are promising for the treatment of chronic wounds (Table 1). 
Mai et al. [6] investigated the ointment Sulbogin
®
 (marketed as Suile
TM
), comprised of borneol (a 
bicyclic monoterpenoid alcohol), bismuth subgallate and Vaseline
®
, and found it to hasten excision 
wound closure in adult male Sprangue-Dawley rats. Although the specific mechanism remains elusive, 
it is thought that bismuth subgallate may induce macrophages to secrete growth factors to facilitate 
wound healing. It was found to decrease the lesion area, enhance granulation tissue formation and  
re-epithelialization, initiate the proliferation of collagen via the activation of fibroblasts, accelerate the 
reestablishment of blood vessels, and restrict the formation of nitric oxide (NO) [4,6].  
The monoterpenoid phenol, thymol, demonstrates multiple beneficial bioactivities toward the 
healing of wounds. These attributes encompass the modulation of prostaglandin synthesis [7], 
imparting anti-inflammatory effects in neutrophils, the inhibition of myeloperoxidase activity and a 
decreased influx of leukocytes [8,9], positive antioxidant effects on docosahexaenoic acid (an omega-3 
fatty acid) concentrations [10], the prevention of lipid autoxidation [11] and formation of toxic 
elements via the stimulation of reactive nitrogen species [12], and antimicrobial activity [13,14]. The 
capacity of thymol for direct wound healing involves its being correlated with elevated concentrations, 
in the central nervous system, of macrophage MIF, as well as enhanced anti-inflammatory related 
tissue granulation. Furthermore, it influences collagen synthesis and fibroblast metabolism, leading to 
augmented fibroblast growth in vitro [9]. 
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Table 1. Monoterpenes in wound healing. 
Monoterpene 
Company  
(FDA Approval) 
Composition Mechanism Clinical Trials 
Sulbogin®  
(SuileTM) 
ointment wound 
dressing 
Hedonist 
Biochemical 
Technologies Co, 
Taipei, Taiwan 
(2001, 2003) 
0.7% borneol, 
4.5% bismuth 
subgallate, 
Vaseline® 
bismuth subgallate induces macrophages to secrete 
growth factors to facilitate wound healing [6] 
decreases lesion area, enhances granulation tissue 
formation and re-epithelialization, initiates 
proliferation of collagen via the activation of 
fibroblasts, accelerates reestablishment of blood 
vessels, restricts the formation of nitric oxide [4] 
 Indicated for first- and second-degree burns, partial-thickness wounds, donor 
sites and abrasions. 
 In a study evaluating the effect of bismuth subgallate on biopsy punch wounds 
on Wistar rats, bismuth subgallate had a statistically significant improvement in 
the area of ulceration (day 1), distance between epithelial edges (day 4), and 
area of granulation tissue (day 7, 11, 18) compared to control. No significant 
histological differences were identified between the test and control [15]. 
 A study of adult male rats with full-thickness wounds were evaluated using the 
treatment bismuth and borneol, the major components of Sulbogin® with 
control treatment flamazine. The experimental treatment decreased the wound 
lesion area, increased granulation tissue formation and re-epithelialization [6]. 
thymol N/A 
monoterpenic 
phenol which is 
usually found in 
thyme oil 
modulates prostaglandin synthesis [7];  
anti-inflammatory; inhibits myeloperoxidase 
activity [8,9]; oxidant effects on docosahexaenoic 
acid [10]; prevents lipid autoxidation [11] and 
formation of toxic elements via the stimulation of 
reactive nitrogen species [12]; enhances collagen 
synthesis and fibroblast metabolism [9]; 
antimicrobial; anesthetic [16] 
 Wounds dressed with collagen-based containing thymol films showed 
significantly larger wound retraction rates at 7 and 14 days, improved 
granulation reaction, and better collagen density and arrangement [9]. 
 Gelatin films impregnated with thymol have antioxidant and antimicrobial 
properties against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, 
and Pseudomonas aeruginosa [17]. 
α-terpineol N/A 
monoterpene 
alcohol derived 
from pine and 
other oils 
inhibits generation of prostaglandin-endoperoxide 
synthase [18], COX-2 [19], IL-1β [20], IL-6 [21], 
NF-κB [20], TNF-α and NO production [21]; 
increased expression of IL-10; inhibits neutrophil 
influx [22]; antimicrobial [23]; antifungal [24] 
 No clinical trials in wound healing. 
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Table 1. Cont. 
Monoterpene 
Company  
(FDA Approval) 
Composition Mechanism Clinical Trials 
genipin N/A 
fruit extract 
aglycone 
derived from 
iridoid glycoside 
crosslinking agent [25,26]; antioxidant [27];  
anti-inflammatory [28]; stimulates NO production; 
inhibits lipid peroxidation; elevates potential of 
mitochondrial membranes; elevates secretion of 
insulin; increases ATP levels; closes KATP 
channels [29] 
 No clinical trials in wound healing. 
 Genipin hydrogels [30], nanogels [31], and genipin cross-linked scaffolds [32] 
have potential application in skin tissue engineering [33] and wound dressings 
[34–36] and demonstrate excellent biocompatibility and low cytotoxicity in 
scaffolding models [37,38]. In biomaterials studies, genipin-crosslinked gels 
enhance fibroblast attachment [39] and vascularization of engineered  
tissues [38,40] and exhibit bacterial inhibition [41]. 
 Genipin-crosslinked gelatin-silk fibroin hydrogels have been shown to induce 
pluripotent cells to differentiate into epidermal lineages [42]. Genipin as a 
crosslinking agent is also utilized in controlling drug delivery in multiple 
systems [43]. 
aucubin N/A 
iridoid glycoside 
found in plants 
anti-inflammatory [44], antimicrobial, antioxidant, 
chemopreventive agent 
 No clinical trials in wound healing. 
 In a study of male mice with full-thickness buccal mucosal oral wounds, 0.1% 
aucubin-treated mice demonstrated earlier re-epithelization and matrix 
formation and decreased numbers of inflammatory cells compared to  
saline-treated controls at 1, 3, and 5 days, suggesting utility of topical aucubin 
in oral wound healing [45]. 
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Table 1. Cont. 
Monoterpene 
Company  
(FDA Approval) 
Composition Mechanism Clinical Trials 
d-Limonene N/A 
orange-peel 
derived terpene 
d-Limonene  
anti-angiogenic, anti-inflammatory; decreases 
systemic cytokines; inhibits expression of  
endothelial P-selectin 
 No clinical trials in wound healing. 
 Topical d-Limonene and its metabolite perillyl alcohol were tested in murine 
models of chemically-induced dermatitis and mechanical skin lesions. Both 
significantly reduced the severity and extent of chemically-induced dermatitis. 
Lower levels of the inflammatory cytokines IL-6 and TNF-α, reduced 
neovascularization, and lower levels of P-selectin expression were observed in 
both models. Both d-Limonene and perillyl alcohol demonstrated anti-
inflammatory effects in wound healing. Together, these effects contribute to the 
wound healing effects of d-Limonene [46]. 
 Nanophyto-modified wound dressings with limonene are resistant to 
Staphylococcal and Pseudomonal colonization and biofilm formation compared to 
uncoated controls [47]. 
 Topical limonene and other terpenes can increase permeation of silver 
sulphadiazine by increasing its partitioning into eschars. Burn wound 
antimicrobial therapy may be improved through the use of terpenes [48]. 
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Table 1. Cont. 
Monoterpene 
Company  
(FDA Approval) 
Composition Mechanism Clinical Trials 
sericin N/A 
protein created  
by silkworms 
(Bombyx mori) 
stimulates migration of fibroblasts; generates 
collagen in wounds, leading to activation of 
epithelialization; anti-inflammatory; initiates 
propagation and attachment of skin fibroblasts  
and keratinocytes 
 Double blinded randomized controlled trial (RCT) of 65 burn wounds of 
greater than 15% total body surface area (TBSA) were randomly assigned to 
either control (silver zinc sulfadiazine cream) or treatment (silver zinc 
sulfadiazine cream with sericin cream at a concentration of 100 μg/mL). Time 
to complete healing was significantly shorter for the treatment group  
(22.42 ± 6.33 days) compared to the control group (29.28 ± 9.27 days).  
No infections or adverse reactions were found in any of the wounds [49]. 
 A clinical study on silk sericin-releasing wound dressing was compared to the 
wound dressing Bactigras® in a clinical trial in patients with split-thickness skin 
graft (STSG) donor sites. The sericin dressing was less adhesive to the wound 
and potentially less traumatic. Wounds treated with the silk sericin dressing 
exhibited significantly faster rates to complete healing (12 ± 5.0 days compared 
to 14 ± 5.2 days) and significantly reduced pain during the first four days post-
operatively [50]. In rat models, silk sericin dressing also demonstrated 
accelerated wound healing and greater epithelialization and type III collagen 
formation in full-thickness wounds [51–53]. 
 Several animal studies conclude that sericin promotes the wound healing 
process without causing inflammation [54]. Sericin treated full-thickness skin 
wounds in rats demonstrated less inflammation, greater wound size reduction 
and shorter mean time to healing compared to control (betadine treated full-
thickness skin wounds). Examination after 15 days of 8% sericine treatment 
revealed complete healing, increased collagen formation, and no ulceration 
compared to cream base-treated wounds which demonstrated inflammatory 
exudates and ulceration [55]. 
 3D hydrogels [56] and cultured fibroblasts and keratinocytes on three-
dimensional sericin matrices can potentially be used as skin equivalents in 
wound repair [57]. 
 Sericin/chitosan composite nanofibers demonstrate wide spectrum bactericidal 
activity [58]. Sericin enriched wound dressings represent significant promise in 
wound healing biologics [35,59,60]. 
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The monoterpenoid alcohol, α-terpineol conveys its wound healing [61] and anti-inflammatory 
activities via the inhibition of the generation of prostaglandin-endoperoxide synthase enzymes [18], 
cyclooxygenase-2 (COX-2) [19], interleukin-1 beta (IL-1β) [20] and IL-6 cytokines [21], nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) [20], TNF-α and NO production [21]. Increased 
expression of the anti-inflammatory cytokine interleukin 10 (IL-10) is also observed. Additionally, it 
exhibits inhibitory effects on neutrophil influx [22], as well as robust antimicrobial [23] and antifungal 
activities [24]. Significant activity in tissue/scar formation is also observed with α-terpineol [61].  
Cross-linkers are one of the many factors that affect the mechanical and biological properties of 
scaffolds used in tissue engineering. The iridoid (a secondary monoterpenoid metabolite) compound 
genipin may serve as a biocompatible crosslinking agent that imparts minimal cytotoxicity [25,26]. 
Additionally, it is an antioxidant [27] and anti-inflammatory that stimulates the generation of NO while 
inhibiting lipid peroxidation [28]. It also serves to elevate the potential of mitochondrial membranes, to 
elevate the secretion of insulin, to increase adenosine triphosphate (ATP) levels and to close potassium 
channels (KATP) [29], among other positive effects in wound healing [36,62]. Aucubin (an iridoid 
glycoside) was found to have beneficial pharmacological activities on a number of fronts, 
encompassing dermal wound healing [44,45,63], and capacities as an anti-inflammatory [44], 
antimicrobial [64], and antioxidant [65]. In addition to various specific biochemical effects, it also 
shows promise as a non-cytotoxic chemopreventive agent [66].  
D’Alessio et al. [46] revealed that the prototype monoterpene d-Limonene in combination with its 
metabolite perillyl alcohol, which is derived from orange-peel, exhibited considerable anti-angiogenic, 
anti-inflammatory properties, epidermal repair and wound healing effects in murine models.  
These compounds also lowered the generation of systemic cytokines and inhibited the expression of 
endothelial P-selectin. Topical treatment resulted in more rapid and improved wound closure. 
Aramwit et al. [49] revealed that a protein derived from the silkworm cocoon called silk sericin 
acted to enhance the capacity for wound (second-degree burns) healing when incorporated into a 
common silver zinc sulfadiazine antimicrobial cream. At a concentration of 100 μg/mL, sericin was 
shown to stimulate the migration of fibroblasts. Siritientong et al. [35] discovered that silk sericin had 
the capacity to generate collagen in wounds, which led to the activation of epithelialization. Further, it 
served to reduce inflammation [67] and to initiate the propagation and attachment of human skin 
fibroblasts and keratinocytes [55,68,69]. 
2.3. Contraindications 
Contraindications for biologics such as the monoterpenes are low. Acute toxicity of the 
monoterpenes is low via the oral and dermal routes of exposure in animal models [70]. 
3. Skin Substitutes for Wound Healing 
3.1. Description 
Skin substitutes are tissue-engineered products designed to replace, either temporarily or 
permanently, the form and function of the skin. Skin substitutes are often used in chronic, non-healing 
ulcers, such as pressure ulcers, diabetic neuropathic ulcers and vascular insufficiency ulcers.  
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These wounds contribute to substantial morbidity such as increased risk for infection, limb amputation, 
and death. Skin substitutes have the potential to improve rates of healing and reduce complications in  
a variety of other skin wounds including, but not limited to, wounds from burn injuries, ischemia, 
pressure, trauma, surgery and skin disorders. Skin substitutes are also used in patients whose ability to 
heal is compromised and in situations where skin coverage is inadequate. Goals for treating acute and 
chronic wounds with skin substitutes are to provide temporary coverage or permanent wound closure, 
to reduce healing time, to reduce post-operative contracture, to improve function, and to decrease 
morbidity from more invasive treatments such as skin grafting. 
Skin substitutes can be categorized according to whether they are acellular or cellular.  
Acellular products, such as cadaveric human dermis with removed cellular components, contain  
a scaffold or matrix of hyaluronic acid, collagen, or fibronectin. Cellular products contain living cells 
such as keratinocytes and fibroblasts within a matrix. These cells can be autologous, allogeneic,  
or from another species. Skin substitutes can be divided into three major categories: dermal 
replacement, epidermal replacement and dermal/epidermal replacement. They can also be used as 
either permanent or temporary wound coverings. 
A large number of skin substitutes are commercially available or in development. Table 2 details 
epidermal, dermal, and combined, full-thickness skin replacements that have clinical and experimental 
evidence of efficacy in wound healing. Information regarding type of skin replacement, regulatory 
status and year of United States Food and Drug Administration (U.S. FDA) approval, product 
description, indications, clinical and experimental trials according to wound type, and advantages and 
disadvantages for each product are detailed. 
Epidermal skin replacements require a skin biopsy from which keratinocytes are isolated  
and cultured on top of fibroblasts. Epicel
®
 (Genzyme Tissue Repair Corporation, Cambridge, MA, 
USA) is an epidermal skin substitute composed of cultured autogeneous keratinocytes used for 
permanent coverage in partial or full-thickness wounds. Laserskin
®
 (Fidia Advanced Biopolymers, 
Abano Terme, Italy) is composed of autologous keratinocytes and fibroblasts cultured on a  
laser-microperforated biodegradable matrix of benzyl esterified hyaluronic acid. 
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Table 2. Skin substitutes for wound healing. 
Epidermal Skin Replacement 
Biologic Company  
(FDA Approval)  
Product Description 
Product Description 
FDA Indications  
(Other Indications) 
Clinical Trials 
Advantages  
Disadvantages 
Epicel®  
Genzyme Tissue Repair 
Corporation  
Cambridge, MA, USA 
(2007)  
 
Permanent skin substitute  
Living Cell Therapy  
Cultured Epithelial 
Autograft (CEA) 
autologous keratinocytes 
with murine fibroblasts are 
cultured to form epidermal 
autografts which are then 
processed into sheets and 
placed onto petroleum 
gauze [71]. It is used as an 
adjuvant to STSG or alone 
if STSG are not available 
due to  
the extent or severity of the 
burns. 
Humanitarian Device 
Exemption (HDE) for 
treatment of deep dermal 
or full thickness burns 
(greater than or equal to 
30% TBSA); grafting 
after congenital nevus 
removal  
 
(diabetic and venous 
ulcers) 
Burns 
 No RCT have been conducted to evaluate the effectiveness of this product in 
improving health outcomes for deep dermal/full thickness burns. 
 In a large, single center trial, Epicel® CEA was applied to 30 burn patients 
with a mean TBSA of 37% ± 17% TBSA. Epicel® achieved permanent 
coverage of a mean of 26% TBSA compared to conventional autografts 
(mean 25%). Final CEA take was a mean 69% ± 23%.  
Ninety percent of these severely burned patients survived [72]. 
Advantages 
 Use of autologous cells 
obviates rejection 
 Permanent large area wound 
coverage, especially in 
extensive burns [73] 
Disadvantages 
 Long culture time (3 weeks) 
 Variable take rate 
 Poor long-term results 
 1 day shelf life [74] 
 Expensive 
 Risk of blistering, 
contractures, and infection 
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Table 2. Cont. 
Epidermal Skin Replacement 
Biologic Company  
(FDA Approval)  
Product Description 
Product Description 
FDA Indications  
(Other Indications) 
Clinical Trials 
Advantages  
Disadvantages 
Laserskin®  
Fidia Advanced 
Biopolymers  
Abano Terme, Italy  
 
Permanent skin substitute 
autologous keratinocytes 
and fibroblasts derived 
from a skin biopsy 
cultured on  
a laser-microperforated 
biodegradable matrix of 
benzyl esterified 
hyaluronic acid [75,76]. 
Cells proliferate and 
migrate through the 
matrix. Microperforations 
allow for drainage of 
wound exudate. 
(diabetic foot ulcers and 
venous leg ulcers, 
partial thickness burns, 
vitiligo) [77,78] 
Diabetic Foot Ulcers (DFUs) 
 A multicenter RCT with unhealed (≥1 month) DFUs randomized 180 
patients to receive intervention (Hyalograft-3D® autograft and then 
Laserskin® autograft after two weeks) or control (paraffin gauze). At 12 
weeks, a 50% reduction in the intervention group was achieved significantly 
faster compared to control (40 versus 50 days). Complete ulcer healing was 
similar in both groups. The rate of ulcer reduction was greater in the 
treatment group. There was a significantly (3.65-fold) better chance of 
wound healing in a subgroup of hard-to-heal ulcers following autograft 
treatment of dorsal ulcers [79]. 
 In a study of chronic (>6 months) foot ulcers over 15 cm2 in type 2 
diabetic patients older than 65 years treated with Hyalograft-3D® and 
Laserskin® autograft, all ulcers healed at 12 months except for one, with a 
median healing time of 21 weeks [80]. 
 In a study of 14 patients with chronic (>6 months), non-healing foot ulcers 
secondary to type 2 diabetes treated with Laserskin® autograft, 11/14 lesions 
were completely healed between 7 and 64 days post-transplantation [81]. 
Wounds 
 In a retrospective observational study in 30 patients with chronic wounds not 
responding to conventional therapy, keratinocytes on Laserskin® to treat 
superficial wounds or fibroblasts on Hyalograft-3D® to treat deep leg ulcers 
were applied; the wounds were then dressed with nanocrystalline silver 
dressing. A reduction in wound dimension and exudates and an increase in 
wound bed score was observed. The group treated with keratinocytes had a 
significantly greater degree of healing compared to those treated with allogenic 
fibroblasts [82]. 
 Collagen matrices such as Integra® have been poor recipients of cultured 
keratinocytes, although some studies report successes in the use of Laserskin® 
on the neodermis of Integra® after the silicone membrane is removed 14–21 
days post-grafting [83,84]. 
Advantages 
 Use of autologous cells 
obviates rejection 
 Can be produced in shorter 
period of time than confluent 
epidermal sheets 
 Does not require the use of 
the enzyme dispase to 
remove the sheets from 
culture flasks, in contrast to 
CEA 
 Good graft take 
 Low rate of infection 
 Ease of handling during 
application 
 Transparency allows wound 
to be visualized during 
dressing changes 
Disadvantages 
 Only available in Europe 
 2 day shelf life 
 Expensive 
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Table 2. Cont.  
Dermal skin replacement 
Biologic Company  
(FDA Approval)  
Product Description 
Product Description 
FDA Indications  
(Other Indications) 
Clinical Trials 
Advantages  
Disadvantages 
TransCyte® 
Shire Regenerative 
Medicine, Inc. 
San Diego, CA, USA;  
Smith & Nephew, Inc., 
Largo, FL, USA (1997) 
 
Temporary skin substitute 
Composite matrix 
human 
allogeneic 
fibroblasts from 
neonatal 
foreskin seeded 
onto silicone 
covered 
bioabsorbable 
nylon mesh 
scaffold and 
cultured ex vivo 
for 4–6 weeks, 
secreting 
components of 
the extracellular 
matrix and 
many local 
growth  
factors [85] 
temporary 
covering of 
deep partial 
thickness and 
full thickness 
burn wounds 
 
(chronic leg 
ulcers 
(diabetic foot 
ulcers lasting 
more than 6 
weeks; venous 
and pressure 
ulcers) 
Burns 
 33 children with partial-thickness burn wounds were randomized to 
receive TransCyte®, Biobrane®, or Silvazine cream. Mean time to  
re-epithelization was 7.5 days, 9.5 days, and 11.2 days, respectively. 
Wounds requiring autografting were 5%, 17%, and 24%, respectively. 
TransCyte® promoted faster re-epithelization, required fewer dressings, 
and required less autograft compared to those treated with Biobrane® or 
Silvazine [86]. 
 In a randomized prospective study of 21 adults with partial-thickness burn 
wounds to the face, patients treated with TransCyte® had significantly 
decreased daily wound care time (0.35 ± 0.1 versus 1.9 ± 0.5 h),  
re-epithelialization time (7 ± 2 versus 13 ± 4 days), and pain (2 ± 1 vs. 4 ± 2) 
compared to patients treated with topical bacitracin [87]. 
 20 pediatric patients with TBSA over 7% were treated with TransCyte® 
and compared to previous patients those who received standard therapy of 
antimicrobial ointment and hydrodebridement. Only one child required 
autografting in the TransCyte® group, compared to 7 children in the 
standard treatment group. In addition, children treated with TransCyte® 
had a significantly decreased length of stay (5.9 days) compared to those 
who received standard therapy (13.8 days) [88]. 
 110 patients with deep partial-thickness burns were treated with 
dermabrasion and TransCyte® and compared with data from the American 
Burn Association Patient Registry. Patients with 0–19.9% TBSA burn 
treated with dermabrasion and TransCyte® had a significantly shorter 
length of stay of 6.1 days versus 9.0 days. The authors compared burns of 
all sizes with dermabrasion and TransCyte® and concluded that this 
method of managing partial-thickness burns reduced length of stay 
compared to standard care [89]. 
Advantages 
 Easy to remove compared 
to allograft 
 Widely used for partial-
thickness burns 
 Improved healing rate 
 1.5 year shelf life 
Disadvantages 
 Expensive 
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Wounds 
 A randomized prospective comparison study of TransCyte® and silver 
sulfadiazine on 11 patients with paired wound sites was performed. 
Wounds treated with TransCyte® had significantly quicker healing times 
to re-epithelialization (mean 11.14 days vs. 18.14 days). Wound evaluations 
at 3, 6, and 12 months revealed that wounds treated with TransCyte® 
healed with significantly less hypertrophic scarring than those treated with 
silver sulfadiazine [90]. 
 
Dermagraft® 
Shire Regenerative 
Medicine, Inc. 
San Diego, CA, USA (2001) 
 
Permanent or temporary skin 
substitute 
Living Cell Therapy 
Allogenic matrix derived 
from human neonatal 
fibroblast 
cryopreserved allogenic 
neonatal fibroblasts 
derived from neonatal 
foreskin and cultured on 
bioabsorbable collagen on 
polyglactin (Dexon) or 
polyglactin-910 (Vicryl) 
mesh for several  
weeks [91]. The 
biodegradable mesh 
disappears after 3–4 weeks 
Premarket approval 
(PMA) for full-thickness 
diabetic lower extremity 
ulcers present for longer 
than 6 weeks extending 
through the dermis but 
not to the tendon, muscle, 
or bone [92] 
 
(Chronic wounds, and 
noninfected wounds. It 
can be used as a 
temporary or permanent 
covering to support take 
of meshed STSG on 
excised burn  
wounds [93,94]) 
DFUs 
 A multicenter RCT with 314 patients with chronic DFUs to Dermagraft® 
or conventional therapy was performed. At 12 weeks, 30% of the 
Dermagraft® patients had complete wound closure compared to 18.3% of 
control patients. Although the incidence of adverse events was similar for 
both groups, the Dermagraft group (19%) experienced significantly fewer 
ulcer-related adverse events (infection, osteomyelitis, cellulitis) compared 
to the control group (32.5%) [95]. 
 A prospective, multicenter RCT in 28 patients with chronic DFUs  
(>6 weeks duration) comparing intervention (Dermagraft® + saline gauze) 
to control (saline gauze) was performed. By week 12, significantly more 
DFUs healed in the intervention (71.4%) compared to the control (14.3%). 
Wounds closed significantly faster in patients treated with Dermagraft® 
and the percentage of patients with wound infection was less in the 
Dermagraft® group [96]. 
Advantages 
 Semitransparency allows 
continuous observation of 
underlying wound surface 
 Cell bank fibroblasts have 
been tested for safety and 
there have been no safety 
issues thus far 
 Easier to remove and higher 
patient satisfaction compared 
to allograft [94] 
 Equivalent or better than 
allograft for graft take [93], 
wound healing time, wound 
exudate and infection 
 No adverse reactions, such as 
evidence of rejection [93] 
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DFUs 
 The DOLCE trial (ID: NCT01450943) is a randomized, single-blind, 
comparative trial to compare the differences among acellular matrices 
(Oasis® (Healthpoint, Ltd Fort Worth, TX, USA), cellular matrices 
(Dermagraft® (Shire Regenerative Medicine, Inc.), and standard of care in 
the treatment of DFUs using the primary outcome of complete wound 
closure by 12 weeks [97]. 
 A multicenter clinical trial of Dermagraft® in the treatment of DFUs in 62 
patients after sharp debridement was performed. Patients received dressing 
changes with saline gauze or polyurethane foam dressings weekly. By 
week 12, 27/62 (44%) patients had complete wound closure, and 32/62 
(52%) healed by week 20. Median time to healing was 13 weeks. 
Dermagraft® was safe and effective in the treatment of non-healing DFUs 
[98]. 
 A prospective multicenter randomized single-blinded study to evaluate 
wound healing in 50 patients with DFUs was performed. Patients were 
randomized into one of four groups (three separate dosages of 
Dermagraft® and one control group). A dose response curve was observed 
and ulcers treated with the highest dosage of Dermagraft® healed 
significantly more than those treated with conventional wound closure 
methods. 50% (6/12) of the Dermagraft® and 8% (1/13) of the control 
ulcers healed completely. The percentage of ulcers to complete closure 
was significantly greater in the Dermagraft® group (50% or 6/12) 
compared to the control group (8% or 1/13) [99]. 
Disadvantages 
 Used for temporary coverage 
 6 month shelf life 
Contraindications 
 Clinically infected ulcers 
 Ulcers with sinus tracts 
 Hypersensitivity to bovine 
products 
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Venous leg ulcers 
 A prospective multicenter RCT to evaluate Dermagraft® + compressive 
therapy versus compressive therapy alone in the treatment of venous leg 
ulcers was conducted. For ulcers ≤12 months duration, 49/94 (52%) 
patients in the Dermagraft® group versus 36/97 (37%) patients in the 
control group healed at 12 weeks and this was statistically significant. For 
ulcers ≤10 cm2, complete healing at 12 weeks was observed in 55/117 
(47%) patients in the Dermagraft® group compared with 47/120 (39%) 
patients in the control group, and this was statistically significant. Both 
groups experienced similar rates of adverse events [100]. 
 A prospective RCT in 18 patients with venous leg ulcers treated with 
Dermagraft® + compression therapy or compression therapy alone was 
performed. Healing was assessed through ulcer tracing and planimetry. 
The rate of healing was significantly improved in patients treated with 
Dermagraft® [101]. 
 
AlloDerm®/ 
Strattice® 
LifeCell Corporation 
Branchburg, NJ, USA 
(1992) 
 
Permanent skin substitute 
Living Cell Therapy 
Human skin allograft derived 
from donated human cadaver 
lyophilized human 
acellular cadaver dermal 
matrix serves as a 
scaffold for tissue 
remodeling [85] 
Burns, full thickness 
wounds [102] 
 
(breast surgery [103–105], 
soft tissue 
reconstruction [106]) 
Burns 
 Three patients with full-thickness burns of the extremities were treated with 
AlloDerm® dermal grafts followed by thin autografts. Functional 
performance and aesthetics were considered good to excellent [107]. 
 The average graft take rate in 12 patients with full-thickness burn injuries in 
joint areas was 91.5% at one year post AlloDerm® with ultrathin autograft. 
All patients had near normal range of motion at one year and aesthetic 
results were judged fair to good by both surgeons and patients [108]. 
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Wounds 
 36 patients with oral mucosal defects reconstructed 
with AlloDerm® grafts were evaluated. 34/36 cases 
(94.4%) were successfully replaced with mucosa and 
2 grafts failed. Graft contraction occurred in 7/34 
(20.6%) of patients with lip or buccal defects [109]. 
Advantages 
 Immediate permanent wound coverage 
 Allows grafting of ultra-thin STSG as one-stage procedure 
 Template for dermal regeneration 
 Immunologically inert since the cells responsible for immune response and graft 
rejection are removed during the processing 
 Reduced scarring 
 Can vascularize over exposed bone and tendon 
 2 year shelf life 
 Good aesthetic and functional outcomes (less hypertrophic scar rates, good 
movement) 
 Injectable micronized form is also available (Cymetra®) 
Disadvantages 
 Risk of transmission of infectious diseases, although no cases of viral 
transmission have been reported 
 No viral or prion screening 
 Collection fluid risk (seroma, hematoma, infection) 
 Possibility of donor rejection 
 Expensive 
 Requires two procedures 
 Inability to replace both dermal and epidermal components simultaneously 
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Biobrane® 
Smith & Nephew, St. 
Petersburg, FL, USA 
 
Temporary skin substitute 
Acellular matrix 
acellular dermal matrix 
made of porcine type I 
collagen that is 
incorporated onto a 
porous nylon mesh with 
a silicone membrane. 
The semipermeable 
membrane allows for 
penetration of antibiotics, 
drainage of exudates, and 
control of evaporative 
water losses. The nylon 
and silicone membrane 
allow for adherence to 
the wound surface [110]. 
Partial thickness burns 
within 6 hours and donor 
sites of split thickness 
skin grafts [111] with 
low bacterial counts and 
without eschar or  
debris [112]; treatment 
of toxic epidermal 
necrolysis [113] and 
paraneoplastic 
pemphigus  
 
(dermabrasion, skin-graft 
harvesting, and laser 
resurfacing, chronic 
wounds, venous  
ulcers [110]) 
Burns 
 In a retrospective chart review of children aged 4 weeks to 18 years with 
an average of 6% TBSA partial thickness burns, patients with Biobrane® 
healed significantly faster compared than those treated with beta glucan 
collagen (9 days vs. 13 days). Patients requiring inpatient treatment had 
shorter length of hospital stay (2.6 vs. 4.1 days) [114] 
 In a prospective randomized study in pediatric patients with partial 
thickness burns, Biobrane® was compared to topical application of 1% 
silver sulfadiazine. Pain, pain medication requirement, wound healing 
time, and length of stay (LOS) were significantly reduced in the Biobrane® 
group [115]. 
 In a retrospective review, Biobrane® promoted adherence of split thickness 
skin grafts to the wound, allowing fluid drainage and preventing shearing. 
Biobrane® also facilitated healing of adjacent donor site or partial 
thickness burns [116]. 
 In a controlled clinical trial of patients with partial thickness burns, 
compared to 1% silver sulfadiazine applied twice daily with dry gauze and 
elastic wraps, Biobrane® decreased healing time by 29% (10.6 days vs. 
15.0 days) and reduced pain and the use for pain medication (0.6 vs. 3.0 
tablets) at 24 h. There was no difference in the rate of infection [117]. 
 In a prospective study of patients with scalp defects >5 cm requiring 
removal of periosteum, the biosynthetic dressing was definitive in six 
patients and complete closure was achieved in 3.5 months [118]. 
 In a prospective RCT of children with intermediate thickness burns with 
TBSA <10%, no significant difference in time to healing or pain scores 
were detected between use of Biobrane® or Duoderm®, although 
Biobrane® was more expensive [119]. 
Advantages 
 Dressing naturally separates 
from wound 
 Reserved for fresh wounds 
(<48 h) with low bacterial 
counts 
 Porous material allows for 
exudate drainage and 
permeability to antibiotics 
 Higher infection rates than 
other dressings [120] 
 Reduces pain levels and 
nursing requirements when 
compared to traditional 
dressings [121] 
 Shortens LOS 
 Biobrane-L® available for less 
aggressive adherence [122] 
Disadvantages 
 Does not debride dead 
tissue [117] 
 Permanent scarring in 
partial-thickness scald 
wounds [123] 
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Burns 
 In a prospective RCT of 89 children treated within 48 hours of a 
superficial-thickness scald burn of 5%–25% TBSA randomized to 
Biobrane® or conservative treatment with topical antimicrobials and 
dressing changes, patients treated with Biobrane® had significantly shorter 
time to healing and length of stay. There was no difference in the use of 
systemic antibiotics or readmission for infections [124]. 
 In a prospective RCT comparing Biobrane®, Duoderm®, and Xeroform for 
30 skin graft donor sites in 30 patients, donor sites dressed with Xeroform 
had a significantly shorter time to healing of 10.5 days compared to 
Duoderm® (15.3 days) or Biobrane® (19.0 days). Duoderm® was reported 
to be the most comfortable dressing compared to Biobrane® and 
Xeroform. Two infections developed using Biobrane®, one using 
Duoderm®, and none using Xeroform. Biobrane® ($102.57 per patient) 
was the most expensive dressed compared to Duoderm® ($54.88 per 
patient) and Xeroform ($1.16 per patient) [125]. 
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Integra® Dermal 
Regeneration Template 
(DRT) 
Integra Lifesciences 
Corporation  
Plainsboro, Plainsboro, NJ, 
USA (1996) 
 
Permanent skin substitute 
Acellular matrix 
bilayered extracellular 
matrix of cross-linked 
bovine type 1 collagen 
and chondroitin-6-
sulfate 
glycosaminoglycan 
dermal  
replacement [85,126], 
with a thin silicone 
backing which acts as a 
temporary epidermal 
substitute. The product 
facilitates migration of 
macrophages and 
fibroblasts to initiate 
angiogenesis from 
dermal wound bed to 
create granulation tissue 
to support graft or local 
tissue. Once the neo-
dermis is formed, the 
silicone layer is 
removed and the wound 
is permanently closed 
with a STSG on the 
neo-dermis [91]. 
pressure ulcers, venous 
ulcers, diabetic ulcers, 
chronic vascular ulcers, 
surgical wounds (donor 
sites/grafts, post-Moh’s 
surgery, post-laser 
surgery, podiatric, wound 
dehiscence), trauma 
wounds (abrasions, 
lacerations, second-
degree burns, and skin 
tears) and draining 
wounds (approved 
through 510(k) process in 
2002) 
Burns 
 In a multicenter prospective RCT, 106 patients with life-threatening burns 
underwent excision and grafting. Mean burn size was 46.5% ± 15% mean 
TBSA. Epidermal donor sites healed 4 days sooner with Integra® 
compared to autograft, allograft, and xenograft. There was less 
hypertrophic scarring with Integra® [127]. 
 Integra® was applied to surgically clean, freshly excised burn wounds in 
216 burn patients at 13 burn facilities in the United States. The mean total 
body surface area burned was 36.5%. Once the neo-dermis was generated, 
a thin epidermal autograft was placed. The incidence of superficial 
infection at Integra® sites was 13.2% and of invasive infection was 3.1%. 
The mean take rate of Integra® was 76.2% with a median of 95%. The 
mean take rate of epidermal autograft was 87.5% with  
a median take rate of 98%. This study supported the evidence that Integra® 
is a safe and effective treatment in burn care [128]. 
 In a prospective RCT comparing burn wounds treated with Integra®, 
STSG, and the cellulose sponge Cellonex® in 10 adult patients, all 
products demonstrated equal histological and immunohistological findings 
and equal clinical appearance after one year [129]. 
 In a RCT of 20 children with burn size ranging from 58% to 88%, there 
were no significant differences between Integra® and control (autograft-
allograft application) in burn size, mortality, and length of stay. The 
Integra® group had lower resting energy expenditure and increased levels 
of serum constitutive proteins. The Integra® group also had increased bone 
mineral content and density at 24 months and improved scarring 
(vascularity, pigmentation, thickness) at 12 and 24 months [130]. This 
study supported the use of Integra® for immediate wound coverage in 
children with severe burns. 
Advantages 
 Immediate permanent skin 
substitute 
 One of the most widely 
accepted synthetic skin 
substitutes 
 Median take of 85% 
 Two stage procedure 
requiring a minimum of 3 
weeks between the 
application of Integra® and 
STSG [131] 
 More aesthetic compared 
to autograft 
 Safe, effective, and widely 
utilized for burn 
reconstruction [128,132] 
 Integra Flowable Wound 
Matrix® approved through 
510(k) process in 2007 
Disadvantages 
 Complete wound excision 
 High risk of infection and 
graft loss since it is 
avascular [133] 
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Post-excisional treatment 
of life threatening full 
thickness or deep partial 
thickness burn  
injuries [134] where 
autograft is not available 
at the time of excision or 
not desirable due to the 
condition of the patient 
(approved 2001); 
reconstruction of scar 
contractures when other 
therapies have failed or 
when donor sites for 
repair are not sufficient or 
desirable due to the 
condition of the patient; 
chronic lower extremity 
ulcers [91,92] 
 
(soft tissue defects) 
DFUs 
 Prospective study of patients with diabetic, non-infected plantar foot 
ulcers treated with Integra® demonstrated complete wound closure in 7/10 
patients by week 12 with no recurrent ulcers at follow-up [135]. 
 A retrospective case studies review of five patients with DFUs with 
extensive soft tissue deficits and exposed bone and tendon treated with 
Integra® followed by STSG demonstrated complete wound healing despite 
the failure of two grafts. No infections occured and all patients resumed 
ambulation [136]. 
Wounds 
 In a retrospective study of 127 contracture releases with the application of 
Integra® followed by epidermal autograft, 76% of the release sites, range 
of motion and function were rated as significantly improved or maximally 
improved by physicians at a mean post-operative follow-up period of 11.4 
months. Patients expressed satisfaction with the results at 82% of sites. No 
recurrence of contracture was observed at 75% of the sites. Integra® 
offered functional and aesthetic benefits similar to full-thickness grafts 
without the associated donor site morbidity [137]. 
 Twelve patients with large wounds were randomly divided into treatment 
with fibrin-glue anchored Integra® and postoperative negative-pressure 
therapy or conventional treatment. The take rate was significantly higher 
in the experimental treatment group (98% ± 2%) compared to the 
conventional group (78% ± 8%). The mean time from Integra® application 
to allograft was significantly shorter in the experimental group (10 ± 1 days) 
compared to the conventional treatment group (24 ± 3 days), which also 
resulted in shorter length of stay and potentially decreased risks of 
complications such as infection or thrombosis [138]. 
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Wounds 
 With the use of dressings and STSG, Integra® has been used to achieve 
functional and aesthetic coverage in the management of traumatic wounds 
of the hand with osseous, joint, or tendon exposure [139]. 
 In a study of 31 patients who underwent Integra® grafting for 
reconstructive surgery, complications such as silicone detachment, failure 
of the graft, and hematoma were observed in nine [131]. 
 
Epidermal/Dermal Skin Replacements (Full-Thickness) 
Biologic Company  
(FDA Approval)  
Product Description 
Product Description 
FDA Indications  
(Other Indications) 
Clinical Trials 
Advantages  
Disadvantages 
Apligraf®/ 
Graftskin® 
Organogenesis, Canton, MA, 
USA (1998, 2001) 
 
Permanent skin substitute 
Living Cell Therapy 
Composite matrix 
cornified epidermal 
allogeneic keratinocytes 
derived from neonatal 
foreskin cultured on a type 
I bovine collagen gel 
seeded with living 
neonatal allogeneic human 
fibroblasts in dermal 
matrix [91] 
Chronic partial and full 
thickness venous stasis 
ulcers and full thickness 
diabetic foot ulcers [140] 
 
(epidermolysis  
bullosa [141], recurrent 
hernia repair, pressure 
sores, burn 
reconstruction) [92] 
Venous Leg Ulcers 
 A Cochrane Review concluded that a bilayer artificial skin used in 
conjunction with compression bandaging increases venous ulcer healing 
compared with a simple dressing plus compression [142]. 
 In a prospective multicenter RCT of 240 patients with hard-to-heal chronic 
wounds (>1 year) receiving either intervention with Graftskin® plus 
compression or compression alone, treatment with Graftskin® with 
compression was significantly more effective than compression therapy 
alone in achieving complete wound closure at 8 weeks (32% vs. 10%) and 
significantly more effective at 24 weeks (47% vs. 19%) [143].A previously 
conducted prospective RCT by the same group revealed similar results [144]. 
Advantages 
 Small wounds require one 
application 
 Improved cosmetic (scar 
tissue, pigmentation, texture) 
and functional outcomes in 
chronic wounds [145] 
 Primary role in treating 
chronic ulcers 
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Burns 
 In a multicenter RCT of 38 patients with STSG wounds, Apligraf® was 
placed over meshed autograft while control sites were treated with meshed 
autograft covered with no biologic dressing or meshed allograft. There 
was no difference in the percent take of meshed split thickness autograft 
with or without Apligraf®. The Apligraf® group demonstrated significantly 
improved vascularity, pigmentation, wound height and Vancouver burn 
scar scores, demonstrating a cosmetic and functional advantage of 
Apligraf® compared to controls [145]. 
Donor site healing 
 A RCT of 60 skin donor sites treated with meshed autograft, meshed 
Apligraf®, or polyurethane film dressing was conducted. The healing time 
with Apligraf® (7.6 days) was significantly shorter than with polyurethane 
film dressing. 
 In a multicenter RCT of 10 patients treated with Apligraf®, Apligraf® 
dermis-only, and polyurethane film for acute STSG donor sites, there were 
no differences among the treatment modalities in establishing basement 
membrane at 4 weeks and there were no differences in other secondary 
outcomes [146]. 
Disadvantages 
 Large wounds may require 
multiple applications 
 5 day shelf life [91] 
 Expensive 
 Potential for viral transmission; 
mothers blood and donor’s 
cells screened; cell banks 
screened for product safety 
 Consider ethics with use of 
biological material: bovine 
collagen (Hindus, Buddhists; 
vegetarians); derived from 
foreskin (Quakers) [147] 
Contraindications 
 Infected wounds 
 Allergy to bovine collagen 
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DFUs 
 In a multicenter RCT of 72 patients comparing Apligraf® and standard therapy 
versus standard therapy alone in the treatment of DFUs, there was a 
significantly shorter time to complete wound closure in the Apligraf® group 
51.5% (17/33) compared to with standard treatment with international 
guidelines 26.3% (10/38) at 12 weeks [148]. 
 In a prospective multicenter RCT of 208 patients randomly assigned to ulcer 
treatment with Graftskin® or saline-moistened gauze (control), 63/112 (56%) 
of Graftskin® patients achieved complete wound healing compared to 36/96 
(38%) in the control at 12 weeks and this result was statistically significant. 
Kaplan-Meier curve to complete closure was also significantly lower for 
Graftskin® (65 days) compared to control (90 days). Osteomyelitis and lower-
limb amputations were less frequent in the Graftskin® group [149]. 
 Treatment with Apligraft® plus good wound care for DFUs results in 12% 
reduction in costs during first year of treatment compared to good wound care 
alone [150]. 
Wounds 
 In a prospective RCT of 31 patients requiring full-thickness surgical excision 
for non-melanoma skin cancer, patients were randomized to receive a single 
application of Apligraf® or to heal by secondary intention. Apligraf® reduced 
post-operative pain in this setting, but it was not determined whether it could 
decrease healing time or result in better aesthetic outcomes [151]. 
 In a prospective controlled clinical trial, 48 deep dermal wounds were 
created and Apligraf®, STSG, or dressing was applied. Apligraf® 
demonstrated more cellular infiltrate but less vascularization compared to 
controls. Apligraf® demonstrated survival of allogeneic cells in acute 
wounds for up to six weeks and was recommended for the management of 
acute surgical wounds [152]. 
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OrCel® 
Forticell Bioscience, 
New York City, NY, 
USA (1998) 
 
Living Cell Therapy 
Composite matrix 
neonatal foreskin derived 
keratinocytes and dermal 
fibroblasts cultured in separate 
layers into a type I bovine 
collagen porous sponge [85]. 
During healing, autologous 
skin cells replace the cells in 
the product. 
Approved for HDE in 2001 for use in patients 
with dystrophic epidermolysis bullosa 
undergoing hand reconstruction surgery to 
close and heal wounds created by surgery, 
including donor sites; PMA approval for 
autograft donor sites in burn patients (overlay 
on split thickness skin grafts to improve 
cosmesis and function) [92] 
 
(chronic diabetic and venous wounds) 
 A randomized matched pairs study 
comparing treatment of split-thickness donor 
site wounds with OrCel® or Biobrane-L® 
revealed that scarring and healing times for 
sites treated with OrCel® were significantly 
shorter than for sites treated with  
Biobrane-L® [153]. 
Advantages 
 9 month shelf life 
Disadvantages 
 Cryopreserved 
 Cannot be used in infected 
wounds, in patients who are 
allergic to any animal 
products, or in patients 
allergic to penicillin, 
gentamycin, streptomycin, or 
amphotericin B 
GraftJacket® 
Wright Medical 
Technology, Inc., 
Arlington, TX, USA, 
licensed by KCI 
USA, Inc., San 
Antonio, TX, USA 
 
Permanent skin 
substitute 
Human skin allograft 
derived from donated 
human cadaver 
micronized acellular human 
dermis with a dermal matrix 
and intact basement 
membrane to facilitate 
ingrowth of blood vessels 
(deep and superficial wounds, sinus tract 
wounds, tendon repair, such as rotator cuff 
repair) [154] 
 
not subject to FDA pre-notification approval as 
it is a human cell or tissue based product 
DFUs 
 Multicenter, retrospective study in the 
treatment of 100 chronic, full thickness 
wounds of the lower extremity in 75 
diabetic patients revealed a 91% healing rate 
and suggested its use in the treatment of 
complex lower extremity wounds. No 
significant differences were observed for 
matrix incorporation or complete healing. 
Mean time to complete healing was 13.8 
weeks [155]. 
Advantages 
 2 year shelf life 
 Pre-meshed for clinical 
application 
 Single application 
 Utilized in both deep and 
superficial wound healing 
Disadvantages 
 Cryopreserved 
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DFUs 
 In a prospective multicenter RCT comparing GraftJacket® with standard of 
care therapies for the treatment of DFUs in 86 patients for 12 weeks, the 
proportion of completely healed ulcers between the groups was 
statistically significant. The odds of healing in the study group were 2.7 
times higher than in the control group. The odds of healing were 2.0 times 
higher in the study group than in the control group when adjusted for ulcer 
size at presentation [156]. 
 A prospective randomized study evaluating diabetic patients with lower 
extremity wounds demonstrated that patients treated with GraftJacket® healed 
significantly faster than those with conventional treatment at 1 month [157]. 
 A prospective single center RCT comparing intervention (sharp debridement 
+ GraftJacket® + mineral oil-soaked compression dressing) to control (wound 
gel with gauze dressing) for the treatment of full-thickness chronic non-healing 
lower extremity wounds in 28 diabetic patients revealed that at 16 weeks, 
12/14 patients treated with GraftJacket® had complete wound closure 
compared to 4/14 patients in the control group. Significant differences were 
observed for wound depth, volume, and area [158]. 
 In a prospective, randomized single blind pilot study of 40 patients with 
debrided diabetic lower extremity wounds, GraftJacket® was compared to the 
hydrogel wound dressing Curasol®. At 4 weeks, there was a significant 
reduction in the ulcer size in the GraftJacket® group compared to debridement 
only. At 12 weeks, 85% of the patients with GraftJacket® healed compared to 
5% of controls [157]. 
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Table 2. Cont. 
Epidermal/Dermal Skin Replacements (Full-Thickness) 
Biologic Company  
(FDA Approval)  
Product Description 
Product Description 
FDA Indications  
(Other Indications) 
Clinical Trials 
Advantages  
Disadvantages 
   
DFUs 
 A retrospective multicenter series in 12 patients with DFUs and complex, 
deep, irregularly-shaped, tunneling sinus tracts treated with GraftJacket 
Xpress Scaffold® (a micronized, decellularized flowable soft tissue scaffold 
that can be delivered through a syringe into the wound cavity) demonstrated 
complete healing in 10/12 patients at 12 weeks [159]. 
 In a prospective case series of 17 patients with debrided, non-infected,  
non-ischemic, neuropathic DFUs treated with a single application of 
GraftJacket® with weekly silicone dressing changes, 82.5% of wounds had 
complete re-epithelialization in 20 weeks, with a mean time to healing of  
8.9 ± 2.7 weeks [160]. 
 
PermaDerm®  
Regenicin, Inc., Little Falls, 
NJ, USA 
 
Permanent skin substitute 
autologous keratinocytes 
and fibroblasts cultured on 
bovine collagen scaffold 
Orphan status approval as 
a permanent skin 
substitute in burns  
 No clinical trials available. 
Advantages 
 No risk of rejection 
 Permanent substitute for 
massive burn injury 
Disadvantages 
 No clinical trials or long-
term studies available 
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Dermal skin replacements provide greater stability to the wound and prevent the wound from 
contracting. Transcyte
®
 (Shire Regenerative Medicine, Inc., San Diego, California, USA; Smith & 
Nephew, Inc., Largo, FL, USA) is composed of human allogeneic fibroblasts from neonatal foreskin 
seeded onto silicone covered bioabsorbable nylon mesh scaffold and cultured ex vivo for 4–6 weeks [85]. 
Transcyte
®
 is often used as a non-living, temporary wound covering for partial- and full-thickness burns 
after excision [161]. A derivative of Transcyte
®
 is Dermagraft
®
 (Shire Regenerative Medicine, Inc., San 
Diego, California, USA), a skin substitute composed of living allogenic fibroblasts incorporated into a 
bioresorbable polyglactin mesh that secretes extracellular matrix (ECM) proteins, collagen, growth 
factors and cytokines into the wound site in the provision of viable living dermal substitute [162,163]. 
Dermagraft
®
 has shown improvement in the treatment of chronic diabetic foot ulcers. 
AlloDerm
®
/Strattice
®
 (LifeCell Corporation, Branchburg, NJ, USA) are lyophilized human acellular 
cadaver dermal matrices which serve as a scaffold for tissue remodeling. Autologous keratinocytes 
may be seeded and cultured on Alloderm
®
 to form an epithelium; together; these can be utilized for 
wound and burn closure. Subsequent to its administration to a wound site, AlloDerm
®
 is shown to 
exhibit cellular infiltration and neovascularization [164]. Biobrane
®
 (Smith & Nephew, St. Petersburg, 
FL, USA) is a synthetic dermis temporary skin substitute composed of inner nylon and outer silicone 
with bovine collagen used for temporary coverage in partial and full-thickness burns. Integra
®
 Dermal 
Regeneration Template (DRT) (Integra Lifesciences Corporation, Plainsboro, NJ, USA) is an example 
of a composite skin graft. It is composed of an outer layer of silicone and a cross-linked bovine type I 
collagen glycosaminoglycan dermal matrix. Once the dermal layer has regenerated, the silicone layer 
is removed and the wound is permanently closed with a split thickness skin graft (STSG) on the  
neo-dermis. Integra
®
 is used for permanent coverage of full-thickness burns when combined with thin 
skin graft. 
Epidermal/Dermal skin replacements are also called as full-thickness skin substitutes and are 
composed of both epidermal and dermal layers. Autologous or allogeneic fibroblasts and keratinocytes 
are used in their preparation. The allogenically derived Apligraf
®
 (Organogenesis, Canton, MA, USA) 
is a bilayered matrix construct similar to a microscopic skin layer. Specifically, it is comprised of a 
lower dermal layer of bovine type 1 collagen combined with human fibroblasts (extracted from 
postnatal foreskin) and an upper layer that consists of human keratinocytes, along with 
granulocyte/macrophage colony-stimulating factors. Apligraf
®
 has been used for permanent coverage 
of non-healing chronic wounds (such as diabetic foot ulcers), surgical wounds, pressure wounds, 
neuropathic wounds and venous insufficiency ulcers. Apligraf
®
 has been observed in vitro to generate 
extracellular matrix structural elements and modulators inclusive of tissue inhibitors of matrix 
metalloproteinases and glycoprotein fibronectin [2]. OrCel
®
 (Forticell Bioscience, New York, NY, 
USA) is a composite matrix composed of keratinocytes and dermal fibroblasts cultured in separate 
layers into a type I bovine collagen porous sponge. It is used in patients with dystrophic epidermolysis 
bullosa undergoing hand reconstruction surgery and at autograft donor sites in burn patients [92]. 
GraftJacket
®
 (Wright Medical Technology, Inc., Arlington, TX, USA, licensed by KCI USA, Inc., San 
Antonio, Texas, USA), is an acellular derivative of human dermis. GraftJacket
®
 was shown to 
facilitate accelerated healing and initiate depth and volume reductions in wounds [156]. PermaDerm
®
 
(Regenicin, Inc., Little Falls, NJ, USA) is a newer product that acts as a permanent skin substitute to 
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cover large burns. It is composed of autologous keratinocytes and fibroblasts cultured on bovine 
collagen scaffold [165]. 
3.2. Contraindications 
Biological skin equivalents such as allogenically derived Apligraf
®
 or Dermagraft
®
 have  
an existing, albeit significantly low, risk of disease transmission due to their allogenicity [162].  
In the case of Apligraf
®
, it has been verified in a number of studies that the cells it delivers are not 
sustained within the wound site beyond six weeks, and has inconsistent effects on the wound basement 
membrane, in vivo collagen composition and vascularization [2,146,152]. 
3.3. Clinical Trial Based Evidence 
Greer et al. [166] compared a number of advanced wound therapies in the treatment of ulcers in 
regard to the proportion of ulcers healed and time to healing. This study reviewed randomized 
controlled trials from the literature (MEDLINE 1995–2013, Cochrane Library, and existing systemic 
reviews), which involved patients who were typically middle-aged white males. The 56 trials 
encompassed lower extremity or foot ulcers, with 35 cases of patients with diabetic ulcers, 20 patients 
with venous ulcers, and one patient with arterial ulcers. The duration of therapies generally spanned 
from 4 to 20 weeks, with a mean ulcer duration from 2 to 94 weeks. The mean ulcer size ranged from 
1.9 to 41.5 cm
2
. Of the advanced wound care products used in these trials, the biological skin 
equivalent Apligraf
®
 demonstrated moderate-strength evidence for enhanced healing, as did negative 
pressure wound therapy. Low-strength evidence was shown for platelet-derived growth factors and 
silver cream in comparison to standard care. For arterial ulcers, there was an improvement in healing 
with biological skin equivalent. Although the evidence was deemed as limited, the conclusion of the 
authors was that several advanced wound care therapies appeared to enhance the number of ulcers 
healed, as well as to reduce the times for healing.  
A clinical randomized, double-blind, standard-controlled study was undertaken, which compared 
burn wounds that were treated with silver zinc sulfadiazine cream (control) against those treated with 
the identical cream that also contained silk sericin. The study involved 29 patients presenting with 65 
burn wounds that covered at least 15% of total body surface areas. It was observed that the typical time 
for attaining 70% re-epithelialization in the sericin group was approximately 5–7 days shorter than the 
control group. The control group required 29.28 ± 9.27 days for complete burn wound healing, while 
the sericin group attained this condition within 22.42 ± 6.33 days with no indication of severe reaction 
or infection in any wound [49]. 
Multiple clinical trials have been conducted with the living skin equivalents Apligraf
®
 and 
Dermagraft
®
. A retrospective controlled trial was undertaken that involved 2517 patients (446 
Apligraf
®
, 1892 Regranex
®
 (a human platelet-derived growth factor topical gel for the treatment of 
lower extremity diabetic neuropathic ulcers), 125 platelet releasates, 54 combined) and found that 
diabetic foot ulcers initially treated with Apligraf
®
 were 31.2% more likely to heal than those 
administered with topical growth factor and 40% more likely to heal than those treated with platelet 
releasates [95]. In a prospective, randomized controlled trial involving 72 patients (33 Apligraf
®
, 39 with 
saline moistened gauze control), it was found that at 12 weeks, full wound closure was observed in 
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51.5% (17 of 33) of Apligraf
®
 patients in contrast to 26.3% (10 of 38) of control patients [148].  
An additional prospective, randomized controlled trial involved 74 patients (38 autograft + Apligraf
®
, 
36 autograft alone or + allograft) with dull and partial thickness burns. It was found at 22 months that 
58% of the Apligraf
®
 sites were deemed of better quality than the controls, with 26% as equivalent and 
16% as worse. Further, Apligraf
®
 treated patients (47%) exhibited normal vascularity in contrast to 6% 
of control patients [145]. 
A prospective, randomized controlled trial with Dermagraft
®
 studied 314 patients (130 Dermagraft
®
, 
115 controls) with diabetic foot ulcers. At 12 weeks, 30% of the Dermagraft
®
 patients were healed in 
comparison to 8.3% of the control patients, who were treated with standard wet-to-dry dressings [95]. 
An additional prospective, randomized controlled trial was undertaken with 18 patients (10 Dermagraft
®
, 
eight controls) with venous ulcers, which revealed that the healing rate after 12 weeks was enhanced 
considerably in those patients treated with Dermagraft
®
 + compression (five patients (50%)) as 
opposed to compression on its own (one patient (12.5%)). In addition, the perfusion of capillaries in 
the Dermagraft
®
 group increased by 20%, in comparison to 4.9% in the compression group [101]. 
4. Biomembranes for Wound Healing 
4.1. Description  
Biocompatible vegetal biomembranes of natural rubber/latex, amniotic, polyurethane and  
poly-DL-lactic acid (PDLLA) comprise a class of versatile interventions for the treatment and healing 
of wounds. Additionally, biomembranes may be impregnated with a wide range of bioactive 
compounds to further facilitate and promote wound healing. 
4.2. Mechanism and Indications 
Human amniotic membranes, such as Biomembrane
®
 (Matrix Company, Ismailia, Egypt) are 
comprised of skin-like fetal ectoderm, consisting of four layers (epithelial, basement membrane, 
connective tissue fibroblasts, and spongy layer), which have demonstrated angiogenic properties.  
The membrane is freeze dried to 5% water content and then gamma irradiated (25 kgy) to ensure 
sterilization. These biomembranes exhibit a 1000-fold improvement in efficacy over split-thickness 
human skin grafts, though the specific mechanisms remain unclear [167,168]. Further, amniotic 
membranes are found to inhibit the alpha smooth muscle protein actin, resulting in a significant 
reduction in the generation of scar tissue in comparison to a moist wound dressing control [169]. 
Additional benefits included decreased pain, protection from infection and control of the loss of 
electrolytes and albumin. 
The polyurethane film, Tegaderm
TM
 (3M, Saint Paul, MN, USA), exhibits gas semi-permeability, 
which acts to augment the rate of epithelialization. This may be due the retention of carbon dioxide, 
which translates to sustaining a low pH. The pain relief that is reportedly associated with this film may 
be the result of the exclusion of atmospheric oxygen, which negates the generation of prostaglandin 
E2, via the oxygen-reliant cyclo-oxygenase system [167,170]. An additional imparted benefit 
secondary to the semi-permeability of Tegaderm
TM
 is the regulation of transforming growth factor beta 
(TGF-β) via the mediation of transepidermal water transfer [171]. It also stimulates the propagation of 
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keratinocytes through the activation of integrins a5 and a6 to encourage enhanced and rapid wound 
healing [172]. 
A biocompatible vegetal biomembrane derived from the Hevea brasiliensis rubber tree exhibited 
the capacity to initiate angiogenesis and re-epithelialization in the chronic ulcers of diabetic patients. 
Its activity in the healing process appears most prominent at the inflammatory stage, where the 
microenvironment is transformed by robust angiogenesis followed by re-epithelialization [173]. 
A non-toxic, biocompatible, biodegradable, and non-carcinogenic crosslinked gelatin hydrogel 
biomembrane was developed for use as a wound dressing via the addition of a naturally occurring 
genipin crosslinking agent, and compared to a glutaraldehyde-crosslinked control. The resulting 
genipin infused biomembrane exhibited considerably less inflammation along with more rapid  
re-epithelialization and subsequent wound healing than the control, which may have been facilitated by 
a lower level of genipin imparted cytotoxicity [36]. 
4.3. Contraindications 
Despite stringent preparation protocols, there might be a very low risk of bacterial or viral 
transmission via the use of human amniotic membranes on open wounds. 
4.4. Clinical Trial Based Evidence 
Adly et al. [167] conducted a randomized, controlled clinical trial to compare the efficacy of an 
amniotic membrane (Biomembrane
®
) group I (23 patients) and a polyurethane membrane 
(Tegaderm
TM
) dressing group II (23 patients) in the treatment of burns (scald and flame). There were 
no notable differences between the two groups. The criteria were inclusion of both genders and all age 
groups with <50% total body surface area affected with either second or third degree burns. The group 
I patients exhibited a considerably lower infection rate (one patient (4.3%) in group I compared to 
three patients (13.0%) in group II) and required fewer dressing changes than group II (highest dressing 
change frequency was once per day in 30.4% of group I patients, in comparison to five times per day 
in 60.9% of group II patients). In addition, electrolyte disturbance was evident in 17.4% of patients in 
group I, compared with 60.9% of patients in group II. Albumin loss was indicated in 39.1% of patients 
in group I in contrast to 60.9% of patients in group II. In terms of pain and healing times, 43.5% of 
group I patients experienced pain during dressing, compared with 60.9% in group II.  
Healing frequency was 47.8% (11–20 days) for group I in contrast to 39.1% in group II spanning the 
same time period. 
5. Scaffolds for Wound Healing 
5.1. Description 
Hybrid scaffolds comprised of polymeric substrates coated with bioactive materials, collagen, silk 
fibroin, as well as advanced tissue engineered substrates impregnated with endothelial progenitor cells, 
and nanomaterial-based scaffolds may be employed as advanced wound dressings to initiate and 
expedite wound healing. 
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5.2. Mechanisms and Indications 
Collagen is a component of the extracellular matrix, which has found established utility as  
a biomaterial in cell therapies and tissue engineering via the provision of a viable substrate for the 
attachment and propagation of cells. In the treatment of wounds, collagen scaffolds offer a feasible 
platform for the topical conveyance of cells into the wound bed, increase the healing of wounds and 
initiate angiogenesis and neovasculogenesis. 
O’Loughlin et al. [174] investigated the use of type 1 collagen scaffolds for the topical delivery of 
autologous circulating angiogenic (CACs) cells (precursors to endothelial progenitor cells), to full 
thickness cutaneous ulcers. It was revealed that the CACs could also be pre-stimulated through the 
addition of matricellular protein osteopontin (OPN), a glycoprotein involved in immune function, 
neovascularization, and facilitation of cell migration and survival [175]. The inclusion of OPN served 
to augment wound healing. It was demonstrated that scaffolds comprised of type 1 collagen, which has 
been shown to sustain angiogenesis [176], when infused with CACs and enhanced with OPN,  
resulted in the formation of larger diameter blood vessels than untreated wounds, and thus acceleration of 
the wound healing process [174].  
Ehashi et al. [177] compared subcutaneously implanted scaffolds for their host body reactions in order 
to assess their wound healing capacities. The scaffolds consisted of collagen coated porous (Ø32 μm and 
Ø157 μm) polyethylene (CCPE), bio-inert poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl 
methacrylate) (PMB) coated polyethylene, and uncoated porous polyethylene (UPPE) (control). 
Subsequent to their immersion in sterile solution for an appropriate period, six samples (two of each 
type with different pore diameters) were implanted under the skins of mouse models, and then resected 
after seven days. In terms of vascularization, it was observed that small vessels were induced on the 
UPPE, albeit contingent on the pore size (more activity seen with Ø32 μm pores than Ø157 μm pores). 
Interestingly, the reverse was true for the CCPE, with more activity seen with the Ø157 μm pore 
sample. There was no vessel growth activity associated with the PMB scaffolds. A deoxyribonucleic 
acid (DNA) microarray assay was then employed to conduct genetic analyses, which showed that the 
CCPE scaffold had a more highly distributed level of gene expression than did the PMB scaffold. The 
PMB scaffold showed the up-regulation of genes associated with the suppression of inflammation. The 
CCPE scaffold indicated up-regulation of genes related to inflammation, angiogenesis, and wound 
healing. The authors concluded that the up-regulation of interleukin-1b and angiogenesis associated 
genes within the porous scaffolds likely contributed to the mediation of tissue regeneration. 
A novel scaffold comprised of electrospun core-shell gelatin/poly(L-lactic acid)-co-poly-(ε-caprolactone) 
nanofibers, which encapsulated a photosensitive polymer poly (3-hexylthiophene) (P3HT) and epidermal 
growth factor (EGF) at its core, was investigated by Jin et al. [178] as a potential skin graft. It was 
found that fibroblast propagation was activated under exposure to light in contrast to its absence and 
cells akin to keratinocytes were found only on the light exposed scaffolds. The researchers propose 
that these light sensitive nanofibers may have utility as a unique scaffold for the healing of wounds and 
the reconstitution of skin. 
Bacterial (or microbial) cellulose has been investigated by Fu et al. [179] for its capacity to enable 
wound healing and skin tissue rejuvenation. Specific bacteria are involved in the biosynthesis of this 
natural polymer, which has unique properties in contrast to plant based cellulose, encompassing 
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biocompatibility, hydrophilicity, high water retention, elasticity, transparency, conformability and the 
capacity for absorbing wound generated exudate during inflammation. These features position 
microbial cellulose to have great potential for biomedical advancements in skin tissue repair. 
5.3. Contraindications 
Scaffolds that are comprised of hyaluronan (an anionic polysaccharide), even though non-cytotoxic 
and biodegradable, may disrupt cell adhesion and the regeneration of tissues due to its hydrophilic 
surface properties [177]. Additional drawbacks for tissue engineered scaffolds in the case of severe 
burns relate to their unreliable adhesion to lesions and failure to replace dermal tissues [180]. 
5.4. Clinical Trial Based Evidence 
The clinical performance of bacterial cellulose (BC) scaffold Dermafill
TM
 (AMD/Ritmed, Tonawanda, 
New York, USA) wound dressings (Acetobacter xylinum derived) was assessed by Portal et al. [181] who 
compared the reduction in wound size of chronic non-healing lower extremity ulcers following 
standard care. A total of 11 chronic wounds were evaluated for the time required to achieve 75% 
epithelization, by comparing non-healing ulcers prior to and following the application of Dermafill
TM
. 
The median observation timeline for chronic non-healing wounds under standard care prior to the 
application was 315 days. When BC scaffolds were applied to these same wounds, the median time to 
75% epithelization was decreased to 70 days. Thus, the authors concluded that BC scaffold-initiated 
wound closure for non-healing ulcers proceeded considerably more rapidly than did standard care 
wound dressings. 
Morimoto et al. [182] investigated the clinical efficacy of a unique synthetic collagen/gelatin 
sponge (CGS) scaffold for the treatment of chronic skin ulcers. This artificial dermal scaffold 
demonstrated the capacity to sustainably release basic fibroblast growth factor (bFGF) over 10 days or 
longer. One of the criteria for the study group was the inclusion of chronic skin ulcers that had not 
healed over a time period of at least four weeks. These wounds treated with CGS, which was infused  
with 7 or 14 μg/cm
2
 of bFGF following debridement, and assessed two weeks subsequent to their 
application. Positive improvement in the wound beds was defined by the emergence of granulated and 
epithelialized areas of 50% or greater. Out of a total of 17 subjects, it was observed that 16 showed 
wound bed improvements, with no discernable difference between the low and high dose groups. 
There was rapid recovery from mild adverse reactions. 
6. Conclusions 
The healing of surface and deep wounds of the epidermis is a complex multistage process, but one 
that may nevertheless be expedited utilizing strategies such as the application of active biologic, 
biomembrane or scaffold based wound dressings. Specific therapeutic compounds and cell species 
including epidermal stem cells may be utilized to impregnate biocompatible and/or biodegradable 
substrates, including membranes and scaffolds to facilitate rapid revascularization, re-epithelialization, 
and healing of wound beds. 
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